SAVA
Cassava Sciences Inc
-13.96%
$29.88 - $25.71
Feb 7th 2023 - Mar 21st 2023
Mar, 15, 2023
$SAVA “Treatment also eased depression and dementi... See more
Feb, 6, 2023
Simufilam reduced dementia-related behavior at 9 m... See more
HEPA
Hepion Pharmaceuticals Inc
-16.85%
$0.86 - $0.72
Feb 7th 2023 - Mar 21st 2023
Mar, 18, 2023
Anyway, since this trial is expensive and yet nece... See more
Jan, 11, 2023
2023 is going to be highlighted with a continuous ... See more
RSLS
ReShape Lifesciences Inc.
-48.86%
$5.91 - $3.02
Feb 8th 2023 - Mar 22nd 2023
Feb, 16, 2023
$RSLS Nice consolidation phase before this one goes.
Feb, 8, 2023
$RSLS nice green boom boom after closed offering ... See more
Mar, 15, 2023
$SAVA “Treatment also eased depression and dementia-related behaviors in patients, two exploratory trial goals, and simufilam was found to be safe and well tolerated.”
Feb, 6, 2023
Simufilam reduced dementia-related behavior at 9 months on the Neuropsychiatric Inventory (NPI), a clinical tool widely used to measure changes in dementia-related behavior.
Feb, 1, 2023
The open label study is a true gift which gives us insight on both health and benefit issues and the med looks great on both counts.
Jan, 17, 2023
$SAVA September 3rd 2021 Remi Barbier said, "I truly believe Cassava Sciences is one clinical program away from greatness.
Jan, 6, 2023
$SAVA Per press release dec 6 2022, Remi stated administration of drug for OL study completed and he is "THRILLED" with the clinical development, or what he see to this date.
Jan, 4, 2023
$SAVA , VERA announced positive phase 2b results meeting primary end point.
Dec, 27, 2022
My prediction: Phase 2 Unbelievable results FDA fast track Phase 3 - go ahead Patients receive sava Market cap 40 B by 2024 Rising to 200 Billion by 2026 Game changer - the only drug in the world to help patients
Mar, 18, 2023
Anyway, since this trial is expensive and yet necessary for regulatory approval; I interpret it as a bullish signal.
Jan, 11, 2023
2023 is going to be highlighted with a continuous cascade of amazingly positive PR’s confirming the fact (already documented in 300+ early clinical studies), that Rencofilstat is truly a Wonder Drug to be celebrated, with an extraordinarily large TAM.
Jan, 11, 2023
$HEPA Was hoping we would get an update on our (Nash) trial soon and we got this surprising good news.
Jan, 9, 2023
I didnt sell a share and with stellar results for this soon to be released study it should gain traction well over 3 imo.
Dec, 28, 2022
We knows recession is coming next year 4) XBI has bottomed and should begin its upward move next year 5) Phase 2b trial results and updates on HCC trial 6) Probable approvals of NASH drugs and increased bullish sentiment in the sector
Dec, 20, 2022
Sign up for the free trial, it's easy.
Dec, 19, 2022
button for good trial results in the NASH space.
Dec, 19, 2022
Highly statistically significant results because of the large trial size.
Feb, 16, 2023
$RSLS Nice consolidation phase before this one goes.
Feb, 8, 2023
$RSLS nice green boom boom after closed offering $FWBI new clinical study news $KPRX $CELZ $ICU
Jan, 3, 2023
$PBLA multiple phase 3 trail ..price 8 cents ..dirt cheap $KALA $RSLS $ATNF $PTPI